Form 4: ALX Oncology Director Granted 40,400 Stock Options

ALX Oncology Holdings Inc. Director and 10% Owner Corey S. Goodman was granted 40,400 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

Summary

• Corey S. Goodman, a Director and 10% Owner of ALX Oncology Holdings Inc. (ALXO), was granted 40,400 stock options.
• The options have an exercise price of $1.32 per share.
• The grant date for these options was January 20, 2026.
• The options will vest in 12 equal monthly installments, commencing on February 20, 2026.
• The expiration date for these stock options is January 19, 2036.
• Following this transaction, Corey S. Goodman beneficially owns 40,400 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director and 10% owner is generally viewed as a positive signal, indicating continued commitment and alignment of interests with shareholders. It incentivizes long-term performance.

Positives

• The grant of stock options to a Director and 10% Owner, Corey S. Goodman, aligns his interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $1.32 provides a clear benchmark for future stock performance required for the options to be in-the-money.

Future Outlook

The vesting schedule of the stock options over 12 equal monthly installments, beginning February 20, 2026, indicates a future alignment of the director's compensation with the company's long-term performance and shareholder value creation.

Industry Context

The grant of stock options to directors and key personnel is a common practice in the biotechnology and pharmaceutical industry, particularly for growth-oriented companies like ALX Oncology. This compensation structure is designed to attract and retain talent, and to align the interests of leadership with long-term shareholder value.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with shareholder value creation.
• Management/Employees: Reinforces the company's compensation strategy to incentivize long-term performance.

Next Steps

• The stock options will begin vesting in 12 equal monthly installments starting February 20, 2026.

Key Dates

Keywords

ALX Oncology, ALXO, Stock Option Grant, Insider Transaction, Corey S. Goodman, Director Compensation, Equity Incentive, Form 4